



Global Health Campus Chemin du Pommier 40 1218 Grand-Saconnex Geneva. Switzerland

theglobalfund.org

Ref.: GMD/SEA/IRN/2021-1112/EBK/AK

25 August 2021

Mr. Claudio Providas Resident Representative United Nations Development Programme (UNDP) No 8 (39), Shahrazad Blvd, Darrous 1948773911 Tehran Islamic Republic of Iran

UNOFFICIAL SUMMARY

This letter comprises two Implementation Letters and serves to amend two separate Grant Confirmations by: (1) approving a reduction of the Program budget for one grant by the amount of unutilized C19RM Funds; and (2) incorporating additional C19RM funds into the Grant and transferring the unutilized C19RM Funds to another grant subject to the terms described below.

Dear Mr. Providas,

Implementation Letter Number: 3¹

Grant Revision: Reduction of Program budget for grant IRN-H-UNDP for

implementation period of 1 April 2018 to 31 March 2021.

Reference is made to the Grant Confirmation dated 5 December 2017 (as amended from time to time, the "Previous Grant Confirmation") between the Global Fund to Fight AIDS, Tuberculosis and Malaria (the "Global Fund") and the United Nations Development Programme (the "Principal Recipient" for grant IRN-H-UNDP (the "Previous Grant"). Unless defined in this Implementation Letter or the context otherwise requires, all capitalized terms used in this letter have the meaning set out in the Previous Grant Confirmation.

The Program budget for the Previous Grant includes funding granted under the Global Fund COVID-19 Response Mechanism ("C19RM Funds") programmed towards activities to respond to the COVID-19 pandemic ("Approved C19RM Activities"). Section 4.1 of the Previous Grant Confirmation provides that C19RM Funds may be carried over to a subsequent Implementation Period upon prior written approval by the Global Fund, provided the C19RM Funds are not used after 30 June 2021.

The amount of C19RM Funds in the Program budget remaining at the end of the Implementation Period (including the remaining in-country C19RM cash balance) for the Previous Grant is US\$

¹ The Previous Grant Confirmation was modified before by Implementation Letter No.1 dated 16 September 2019 and Implementation Letter No.2 dated 20 August 2020.

61,644 ("**Unutilized C19RM Funds**"). The Global Fund has approved the transfer of the Unutilized C19RM Funds from the Previous Grant to grant IRN-H-UNDP with implementation period from 1 April 2021 to 31 March 2024 (the "**Grant**"). As a result, this Implementation Letter decreased the Program budget of the Previous Grant by the Unutilized C19RM Funds.

Implementation Letter Number: 1

Grant Revision: Incorporating additional C19RM funds and addition of

unutilized C19RM funds into Program budget for grant IRN-H-UNDP for implementation period 1 April 2021 to 31

March 2024

Reference is made to the Grant Confirmation dated 2 March 2021 (as amended from time to time, the "Grant Confirmation") between the Global Fund to Fight AIDS, Tuberculosis and Malaria (the "Global Fund") and United Nations Development Programme (the "Principal Recipient") for grant IRN-H-UNDP (the "Grant"). Unless defined in this Implementation Letter or the context otherwise requires, all capitalized terms used in this Implementation Letter have the meaning set out in the Grant Confirmation.

In response to Islamic Republic of Iran's C19RM Full Funding Request, the Global Fund has approved (i) additional funding of USD5,774,447 for COVID-19 support; and (ii) a transfer of unutilized funds of USD61,644 ("Unutilized C19RM Funds") from the 1 April 2018 - 31 March 2021 implementation period for grant IRN-H-UNDP ("Previous Grant") to this Grant, as per the description included in the notification letter sent by the Global Fund to the CCM Chair dated 22 July 2021 (the "C19RM 2021 Full Funding Award").

As a result, this Implementation Letter (i) increases the Grant Funds for the Implementation Period by USD 5,744,447; and (ii) increases the Program budget of the current Grant by the Unutilized C19RM Funds. Accordingly, this Implementation Letter amends the Summary Budget included in Schedule I (*Integrated Grant Description*) of the Grant Confirmation and incorporates the additional covenants to Section 4, as described below, in the Grant Confirmation.

Pursuant to Section 20 of the UNDP - Global Fund Grant Regulations, in order to reflect the above, we propose making the following changes to the Grant Confirmation:

- 1. The table in Section 3 of the Grant Confirmation is hereby deleted and replaced with the revised table annexed to this Implementation Letter.
- 2. The Summary Budget is hereby deleted and replaced with the revised Summary Budget annexed to this Implementation Letter.
- 3. The following new requirements will now be included at Section 4 of the Grant Confirmation:
 - "4.3. The Program budget includes USD 5,836,091 in funding granted under the Global Fund COVID-19 Response Mechanism ("C19RM Funds") programmed towards activities to respond to the COVID-19 pandemic ("Approved C19RM Activities"). Notwithstanding anything to the contrary in the Grant Agreement, C19RM Funds must remain invested in the Approved C19RM Activities and may only be reprogramed or carried over to a subsequent Implementation Period upon prior written approval by the Global Fund, provided that C19RM Funds are not used after 31 December 2023, unless otherwise expressly agreed in writing by the Global Fund".

- 4.4. By 10 October 2021 and no later than 10 January, 10 April, 10 July and 10 October, respectively, for each calendar year of the Implementation Period and any closure period, the Principal Recipient shall complete and submit to the Global Fund's satisfaction, a report setting out the following procurement data:
 - (1) the purchase order issue date;
 - (2) vendor-promised delivery date;
 - (3) date of product dispatch from the manufacturer; and
 - (4) date of product delivery, for each of the following products procured by the Principal Recipient using C19RM funding:
 - (a) "Strategic" and "Mainstream" products; and
 - (b) "Local sourcing advised with enhanced reporting",

as such terms are defined in the Global Fund C19RM Guidelines (as may be amended from time to time, and notified to the Principal Recipient in writing)."

Other than as modified by this Implementation Letter, all provisions of the Grant Agreement for the Previous Grant and the Grant Agreement for the Grant remain the same.

Please confirm your agreement to the amendments to the Previous Grant and the Grant herein by signing this Implementation Letter and returning a copy to the Global Fund by electronic messaging system. These amendments will be effective upon the signing of this Implementation Letter by an authorized representative of Global Fund Grant Financial Management and a fully executed electronic copy of this Implementation letter will be sent to you for your records.

Thank you for your important efforts in the global fight against HIV/AIDS. We look forward to the continued successful implementation of the Program.

Yours sincerely

Nicolas Cantau

Regional Manager

da

South and East Asia

Agreed and signed:
United Nations Development Programme
By:
Name: Claudio Providas
Title: Resident Representative
Date:
Signed by the Grant Finance Manager for the recognition of this agreement by the Global Fund.
Shevone Corbin Grant Finance Manager, Grant Financial Management
Date:
encl.: Annex 1 – Amended Grant Confirmation table for the Grant Annex 2 – Amended Summary Budget for the Grant
cc: CCM Chair Local Fund Agent (UNOPS)

Annex 1

Amended Grant Confirmation table for the Grant

3.1.	Host Country or Region:	Islamic Republic of Iran
3.2.	Disease Component:	HIV/AIDS
3.3.	Program Title:	Enhancement of National HIV Response with Focus on Target Beneficiary Groups in line with fifth National Strategic Plan 2020-2024
3.4.	Grant Name:	IRN-H-UNDP
3.5.	GA Number:	2027
3.6.	Grant Funds:	Up to the amount of USD 16,996,524.00
3.7.	Implementation Period:	From 1 April 2021 to 31 March 2024 (inclusive)
3.8.	Principal Recipient:	United Nations Development Programme N°8 (39), Shahrzad Blvl, Darrous 1948773911 Tehran, Islamic Republic of Iran Attention: Mr. Claudio Providas UNDP Resident Representative in the I.R. Iran Telephone: (009) 821-22869016 Email: claudio.providas@undp.org
3.9.	Fiscal Year:	1 April to 31 March
3.10.	Local Fund Agent:	United Nations Office for Project Services Maison Internationale de l'Environnement 11-13 Chemin des Anémones 1219 Châtelaine, Geneva, Switzerland Attention: Mr. Nayeem Chowdhury Telephone: +8801766450478 Email: nayeemc@unops.org
3.11.	Global Fund contact:	The Global Fund to Fight AIDS, Tuberculosis and Malaria Global Health Campus, Chemin du Pommier 40 1218 Grand-Saconnex, Geneva, Switzerland Attention: Nicolas Cantau Regional Manager Grant Management Division Telephone: +41 58 791 1700 Facsimile: +41 44 580 6820 Email: nicolas.cantau@theglobalfund.org

Annex 2

Amended Summary Budget for the Grant

(text of amended Summary Budget follows)





Country	Iran (Islamic Republic)
Grant Name	IRN-H-UNDP
Implementation Period	01-Apr-2021 - 31-Mar-2024
Principal Recipient	United Nations Development Programme

, , , , , , , , , , , , , , , , , , , ,	one Bevelopine																
By Module	01/04/2021 - 30/06/2021	01/07/2021 - 30/09/2021	01/10/2021 - 31/12/2021	01/01/2022 - 31/03/2022	Total Y1	01/04/2022 - 30/06/2022	01/07/2022 - 30/09/2022	01/10/2022 - 31/12/2022	01/01/2023 - 31/03/2023	Total Y2	01/04/2023 - 30/06/2023	01/07/2023 - 30/09/2023	01/10/2023 - 31/12/2023	01/01/2024 - 31/03/2024	Total Y3	Grand Total	% of Grand Total
COVID-19		\$2,851,463	\$1,519,766	\$780,228	\$5,151,457	\$87,618	\$18,926	\$18,926	\$18,926	\$144,396	\$23,657	\$23,657	\$23,657		\$70,972	\$5,366,825	31.5 %
Differentiated HIV Testing Services	\$224,349	\$32,853	\$439,322	\$32,853	\$729,377	\$249,478	\$32,853	\$468,200	\$32,853	\$783,384	\$274,607	\$32,853	\$32,853	\$32,853	\$373,167	\$1,885,928	11.1 %
Prevention	\$711,912	\$27,015	\$29,933	\$29,933	\$798,794	\$501,156	\$53,550	\$39,041	\$39,041	\$632,787	\$491,944	\$61,685	\$47,176	\$47,176	\$647,980	\$2,079,561	12.2 %
Program management	\$307,116	\$392,616	\$332,765	\$247,683	\$1,280,180	\$418,622	\$202,528	\$227,887	\$195,029	\$1,044,067	\$325,395	\$202,674	\$198,313	\$184,483	\$910,866	\$3,235,113	19.0 %
RSSH: Health management information systems and M&E	\$104,937	\$94,923	\$112,923	\$86,923	\$399,704	\$146,923	\$114,307	\$86,923	\$86,923	\$435,075	\$86,923	\$103,523	\$86,923	\$86,923	\$364,290	\$1,199,069	7.0 %
RSSH: Human resources for health, including community health workers		\$53,908	\$34,047		\$87,956	\$9,432	\$53,908	\$34,047		\$97,388		\$53,908	\$34,047		\$87,956	\$273,299	1.6 %
TB/HIV	\$24,605				\$24,605	\$24,605				\$24,605	\$24,605	5			\$24,605	\$73,814	0.4 %
Treatment, care and support	\$782,879	\$28,285	\$16,963	\$16,963	\$845,089	\$906,839	\$28,285	\$16,963	\$16,963	\$969,049	\$1,068,210	\$28,285	\$16,963	\$16,963	\$1,130,421	\$2,944,559	17.3 %
Grand Total	\$2,155,797	\$3,481,063	\$2,485,719	\$1,194,583	\$9,317,162	\$2,344,672	\$504,357	\$891,987	\$389,735	\$4,130,751	\$2,295,341	\$506,584	\$439,932	\$368,398	\$3,610,255	\$17,058,168	100.0 %
By Cost Grouping	01/04/2021 - 30/06/2021	01/07/2021 - 30/09/2021	01/10/2021 - 31/12/2021	01/01/2022 - 31/03/2022	Total Y1	01/04/2022 - 30/06/2022	01/07/2022 - 30/09/2022	01/10/2022 - 31/12/2022	01/01/2023 - 31/03/2023	Total Y2	01/04/2023 - 30/06/2023	01/07/2023 - 30/09/2023	01/10/2023 - 31/12/2023	01/01/2024 - 31/03/2024	Total Y3	Grand Total	% of Grand Total
Human Resources (HR)	\$286,922	\$336,570	\$376,114	\$376,114	\$1,375,720	\$382,197	\$321,706	\$326,570	\$326,570	\$1,357,042	\$333,599	\$334,572	\$339,436	\$309,028	\$1,316,635	\$4,049,398	23.7 %
Travel related costs (TRC)	\$5,856	\$59,765	\$72,904	\$12,112	\$150,637	\$21,544	\$60,765	\$39,904	\$5,856	\$128,069	\$5,856	\$59,765	\$39,904	\$5,856	\$111,381	\$390,087	2.3 %
External Professional services (EPS)	\$21,710	\$40,227	\$37,096	\$26,096	\$125,129	\$156,096	\$32,481	\$6,096	\$6,096	\$200,769	\$6,096	\$22,696	\$6,096	\$3,696	\$38,584	\$364,482	2.1 %
Health Products - Pharmaceutical Products (HPPP)	\$39,084				\$39,084	\$39,084				\$39,084	\$39,084	ļ			\$39,084	\$117,252	0.7 %

By Cost Grouping	30/06/2021	30/09/2021	31/12/2021	31/03/2022	Total Y1	30/06/2022	30/09/2022	31/12/2022	31/03/2023	Total Y2	30/06/2023	30/09/2023	31/12/2023	31/03/2024	Total Y3	Grand Total	Grand Total
Human Resources (HR)	\$286,922	\$336,570	\$376,114	\$376,114	\$1,375,720	\$382,197	\$321,706	\$326,570	\$326,570	\$1,357,042	\$333,599	\$334,572	\$339,436	\$309,028	\$1,316,635	\$4,049,398	23.7 %
Travel related costs (TRC)	\$5,856	\$59,765	\$72,904	\$12,112	\$150,637	\$21,544	\$60,765	\$39,904	\$5,856	\$128,069	\$5,856	\$59,765	\$39,904	\$5,856	\$111,381	\$390,087	2.3 %
External Professional services (EPS)	\$21,710	\$40,227	\$37,096	\$26,096	\$125,129	\$156,096	\$32,481	\$6,096	\$6,096	\$200,769	\$6,096	\$22,696	\$6,096	\$3,696	\$38,584	\$364,482	2.1 %
Health Products - Pharmaceutical Products (HPPP)	\$39,084				\$39,084	\$39,084				\$39,084	\$39,084				\$39,084	\$117,252	0.7 %
Health Products - Non-Pharmaceuticals (HPNP)	\$896,129	\$395,456	\$378,983		\$1,670,569	\$1,043,693	\$9,000	\$375,582		\$1,428,275	\$1,224,290	\$9,000)		\$1,233,290	\$4,332,134	25.4 %
Health Products - Equipment (HPE)		\$1,290,167	\$111,740	\$102,935	\$1,504,842											\$1,504,842	8.8 %
Procurement and Supply-Chain Management costs (PSM)	\$149,817	\$157,714	\$71,839		\$379,371	\$168,618	\$2,322	\$59,765		\$230,705	\$191,797	\$2,322			\$194,118	\$804,194	4.7 %
Infrastructure (INF)	\$495,984	\$639,912	2		\$1,135,896	\$232,651				\$232,651	\$197,057	,			\$197,057	\$1,565,605	9.2 %
Non-health equipment (NHP)	\$90,051	\$307,802	\$1,223,095	\$573,460	\$2,194,408	\$120,683	\$19,373			\$140,056	\$120,683	\$19,373	3		\$140,056	\$2,474,520	14.5 %
Communication Material and Publications (CMP)	\$1,000		\$25,000		\$26,000	\$1,000				\$1,000	\$1,000				\$1,000	\$28,000	0.2 %
Indirect and Overhead Costs	\$169,242	\$253,449	\$188,949	\$103,866	\$715,506	\$179,106	\$58,711	\$84,070	\$51,213	\$373,100	\$175,878	\$58,857	\$54,497	\$49,817	\$339,049	\$1,427,655	8.4 %
GrandTotal	\$2,155,797	\$3,481,063	\$2,485,719	\$1,194,583	\$9.317.162	\$2.344.672	\$504,357	\$891.987	\$389,735	\$4.130.751	\$2,295,341	\$506,584	\$439,932	\$368.398	\$3.610.255	\$17,058,168	100.0 %

By Recipients	01/04/2021 - 30/06/2021		01/10/2021 - 31/12/2021	01/01/2022 - 31/03/2022	Total Y1		01/07/2022 - 30/09/2022	01/10/2022 - 31/12/2022	01/01/2023 - 31/03/2023	Total Y2		01/07/2023 - 30/09/2023	01/10/2023 - 31/12/2023	01/01/2024 - 31/03/2024	Total Y3	Grand Total	% of Grand Total
PR	\$2,128,234	\$3,416,143	\$2,398,929	\$1,101,538	\$9,044,844	\$2,249,328	\$470,180	\$852,946	\$350,694	\$3,923,148	\$2,254,002	\$464,273	\$392,757	\$321,222	\$3,432,254	\$16,400,246	96.1 %
United Nations Development Programme	\$2,128,234	\$3,416,143	\$2,398,929	\$1,101,538	\$9,044,844	\$2,249,328	\$470,180	\$852,946	\$350,694	\$3,923,148	\$2,254,002	\$464,273	\$392,757	\$321,222	\$3,432,254	\$16,400,246	96.1 %
SR	\$27,562	\$64,920	\$86,790	\$93,046	\$272,318	\$95,344	\$34,177	\$39,041	\$39,041	\$207,603	\$41,339	\$42,312	\$47,176	\$47,176	\$178,002	\$657,923	3.9 %
Center for Disease Control (CDC)	\$13,788	\$31,813	\$40,825	\$47,080	\$133,506	\$49,378	\$16,086	\$16,086	\$16,086	\$97,636	\$18,384	\$18,384	\$18,384	\$18,384	\$73,536	\$304,678	1.8 %
Welfare Organization (WO)	\$13,774	\$33,107	\$45,965	\$45,965	\$138,812	\$45,965	\$18,091	\$22,955	\$22,955	\$109,966	\$22,955	\$23,928	\$28,792	\$28,792	\$104,466	\$353,244	2.1 %
Grand Total	\$2,155,797	\$3,481,063	\$2,485,719	\$1,194,583	\$9,317,162	\$2,344,672	\$504,357	\$891,987	\$389,735	\$4,130,751	\$2,295,341	\$506,584	\$439,932	\$368,398	\$3,610,255	\$17,058,168	100.0 %